Login / Signup

IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection.

Karsten A PilonesMaud CharpentierElena Garcia-MartinezSandra Demaria
Published in: Oncoimmunology (2020)
IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.
Keyphrases
  • dendritic cells
  • nk cells
  • early stage
  • immune response
  • radiation therapy
  • locally advanced
  • cell cycle
  • randomized controlled trial
  • systematic review
  • radiation induced
  • rectal cancer
  • cell proliferation